News & Updates

NGS could guide ovarian cancer treatment

The use of next generation sequencing (NGS) could help identify patients with ovarian cancer who would benefit from targeted therapies, according to a small retrospective study from Korea.

A panel of experts converged to discuss the effect of pain and its recognition as the fifth vital sigh

Expanded benefits for unwed mothers a welcome change, experts say

Earlier this month, Singapore’s Minister for Social and Family Development Tan Chuan-Jin announced that unwed mothers are entitled to 16 weeks of maternity leave from early 2017 and access to a Child Development Account (CDA) from late 2016, funds from which can be used for healthcare expenses, just like married mothers.

ITSH article 2.2

Extended clopidogrel monotherapy after a 9- to 12-month course of dual antiplatelet therapy (DAPT) reduces bleeding and ischaemic events in patients with acute coronary syndrome (ACS) who are at high risk for both events, according to the OPT-BIRISK* trial presented at ESC 2023.

ITSH article 2.1

Bleeding disorders, such as Von Willebrand disease (VWD), platelet function disorder (PFD), thrombocytopenia, and clotting factor deficiencies, are more prevalent among adolescent girls with heavy menstrual bleeding (HMB), according to a study presented at RCOG World Congress 2018.

ACOG article 2.6

Treatment with fezolinetant significantly reduced the frequency and severity of vasomotor symptoms (VMS), particularly hot flashes, in women during their menopausal phase, according to the SKYLIGHT 1* trial presented at ACOG 2022.

ACOG article 2.1

Treatment with fezolinetant significantly reduced the frequency and severity of vasomotor symptoms (VMS), particularly hot flashes, in women during their menopausal phase, according to the SKYLIGHT 1* trial presented at ACOG 2022.

ACOG article 2.7

Treatment with fezolinetant significantly reduced the frequency and severity of vasomotor symptoms (VMS), particularly hot flashes, in women during their menopausal phase, according to the SKYLIGHT 1* trial presented at ACOG 2022.